cysteamine

(redirected from Procysbi)
Also found in: Medical.

cysteamine

(sɪsˈtiːəmɪn)
n
a drug used to treat cystine excretion or radiation sickness
References in periodicals archive ?
M2 PHARMA-July 22, 2019-Horizon Therapeutics Wins US FDA Acceptance of New Drug Application to Make Procysbi Available as Oral Granules in Packets
Food and Drug Administration (FDA) has accepted Horizons New Drug Application (NDA) for PROCYSBI (Cysteamine Bitartrate) Delayed-Release Oral Granules in Packets.
Horizon Pharma announced that the FDA has accepted Horizon's new drug application, or NDA, for Procysbi delayed-release oral granules in packets.
It also adds Procysbi delayed-release capsules and Quinsair (aerosolized form of levofloxacin) global rights, with Procysbi having strong patent protection through 2034.
The most prominent drugs in Raptor's portfolio are Procysbi, used to reduce the toxic concentration of cystine in cells, and Quinsair, approved in the European Union and in Canada for the management of chronic pulmonary infections due to the presence of Pseudomonas aeruginosa bacterium in adult patients with cystic fibrosis.
It adds Procysbi delayed-release capsules and Quinsair (aerosolised form of levofloxacin) global rights, with Procysbi having strong patent protection through 2034.
The company said the FDA's decision on its New Drug Application for RP103 (PROCYSBI) for the potential treatment of nephropathic cystinosis would be delayed by three months.
Procysbi, for the treatment of infantile nephropathic cystinosis, a genetic disease affecting the kidneys;
M2 EQUITYBITES-September 13, 2013-Raptor Pharmaceuticala[euro](tm)s PROCYSBI granted marketing authorisation in EU(C)2013 M2 COMMUNICATIONS http://www.m2.com
M2 PHARMA-September 13, 2013-Raptor Pharmaceuticala[euro](tm)s PROCYSBI granted marketing authorisation in EU(C)2013 M2 COMMUNICATIONS
Horizon Pharma plc (Horizon), a biopharmaceutical company focused on improving patients' lives by identifying, developing, acquiring and commercializing differentiated and accessible medicines that address unmet medical needs, today announced that it has completed the sale of a European subsidiary that owns the marketing rights to PROCYSBI (cysteamine bitartrate) delayed-release capsules and QUINSAIR (levofloxacin nebuliser solution) in Europe, the Middle East and Africa (EMEA) regions to Chiesi Farmaceutici S.p.A.
M2 EQUITYBITES-September 13, 2013-Raptor Pharmaceutical Corp awarded marketing approval for PROCYSBI for proven nephropathic cystinosis in the EU(C)2013 M2 COMMUNICATIONS http://www.m2.com